Sigyn Therapeutics, Inc., a developer of dialysis-like therapies targeting cardiovascular disease and cancer, is exploring strategic transactions including asset sales and a potential merger to navigate financial challenges stemming from its inability to uplist to Nasdaq. CEO Jim Joyce detailed these initiatives in a shareholder update, emphasizing the company's need to raise capital without excessive shareholder dilution.
The company's lead candidate, CardioDialysis, is designed to address cardiovascular disease by reducing cholesterol-transporting lipoproteins and inflammatory molecules. Joyce noted that lipoprotein apheresis devices, which target similar cholesterol components, significantly reduce major adverse cardiovascular events more effectively than drugs, but are limited to fewer than 60 specialized centers in the U.S. CardioDialysis aims to leverage existing dialysis infrastructure, with potential use at over 7,500 U.S. dialysis clinics.
Beyond cardiovascular applications, CardioDialysis shows promise for sepsis treatment, a condition with no currently approved therapy. The device has demonstrated ability to reduce sepsis-inducing bacterial toxins and inflammatory mediators in human blood plasma. Joyce referenced Spectral Medical's PMX hemoadsorption device, which targets endotoxin removal and has achieved a market value of approximately $300 million on the Toronto Stock Exchange. He encouraged stakeholders to follow Spectral Medical's progress at https://www.spectralmedical.com.
Sigyn's strategic pivot follows a failed attempt to uplist from the OTCQB to Nasdaq. The company had secured a firm commitment offering led by a FINRA member broker-dealer but encountered regulatory hurdles when Nasdaq requested investor approval before the SEC deemed the registration statement effective. This created what Joyce described as a "catch-22," ultimately leading to withdrawal of the registration statement.
To address these challenges, Sigyn is considering asset sales and a potential merger with a Nasdaq-listed company facing compliance issues with the exchange's minimum market value requirements. Joyce highlighted these strategies in a previous shareholder update available at https://www.sigyntherapeutics.com/investors/news-events/press-releases/detail/118/sigyn-therapeutics-issues-shareholder-update-highlighting.
The company's development pipeline includes ImmunePrep for optimizing immunotherapeutic antibody delivery in cancer treatment, ChemoPrep for targeted chemotherapy delivery, and ChemoPure for reducing chemotherapy toxicity. These technologies aim to provide strategic value to the dialysis and biopharmaceutical industries.
Sigyn currently has 2,330,042 shares outstanding as of March 11, 2026. While Joyce emphasized that share price and exchange listing do not affect the therapeutic potential of Sigyn's technologies, they significantly impact the company's ability to fund development without diluting shareholder value. The strategic transactions under consideration represent an effort to secure necessary capital while advancing therapies for life-threatening conditions including cardiovascular disease, sepsis, and traumatic brain injury.
